<DOC>
	<DOCNO>NCT01090466</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Giving gemcitabine hydrochloride cisplatin together temsirolimus may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose temsirolimus give together gemcitabine hydrochloride cisplatin first-line therapy treat patient locally advance and/or metastatic transitional cell cancer urothelium .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride , Cisplatin , Temsirolimus First-Line Therapy Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety profile temsirolimus combination cisplatin gemcitabine hydrochloride , include dose-limiting toxicity ( DLTs ) maximum-tolerated dose ( MTD ) patient locally advance and/or metastatic transitional cell carcinoma urothelium . ( phase I ) - To determine recommend dose Phase II stage trial subsequent study . ( phase I ) - To assess progression-free survival ( PFS ) six month date enrollment . ( phase II ) Secondary - To determine pharmacokinetic profile temsirolimus combination cisplatin gemcitabine hydrochloride . ( phase I ) - To determine tolerability ( side-effects ) feasibility ( number participant require dose delay reduction and/or treatment withdrawal ) . ( phase II ) - To determine objective response rate assess RECIST . ( phase II ) - To assess PFS patient . ( phase II ) - To assess overall survival patient . ( phase II ) - To determine toxicity treatment patient . ( phase II ) OUTLINE : This multicenter , phase I dose-escalation study temsirolimus follow phase II study . Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 , cisplatin IV 3-4 hour day 1 , temsirolimus IV 30 minute day 1 2 , 8 9 , 15 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Blood specimen may collect periodically pharmacokinetic study . After completion study treatment , patient follow 6 month 1 year . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelium Pure mixed histology Upper low urinary tract Radiologically evaluable* locally advanced and/or metastatic disease amenable curative treatment surgery radiotherapy , meet 1 follow criterion : T4b , N , M Any T , N23 , M Any T , N , M1 NOTE : *Patients enrol phase II portion trial must radiologically measurable disease . No transitional cell cancer subsequent radical treatment consider view possibly cure disease No history CNS metastases PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ALP ≤ 2.5 time ULN PT INR ≤ 1.5 GFR ≥ 60 mL/min ( uncorrected surface area measure isotopic mean ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Fit receive cisplatincontaining combination chemotherapy No previous malignancy nonmelanoma skin cancer , carcinoma situ cervix , incidental localized prostate cancer No know HIV positivity chronic hepatitis B C infection No symptomatic coronary artery disease , myocardial infarction within past 6 month , congestive cardiac failure ( NYHA class III IV disease ) , uncontrolled symptomatic cardiac arrhythmia No clinically significant bacterial fungal infection PRIOR CONCURRENT THERAPY : At least 1 month since prior radiotherapy radiotherapy involve 30 % total bone marrow volume At least 1 month since prior investigational drug No prior systemic therapy locally advance metastatic disease Patients receive prior neoadjuvant adjuvant chemotherapy urothelial cancer ( 4 course ) , complete least 6 month prior first documented disease progression eligible No concurrent anticoagulant therapy warfarin unfractionated heparin Patients require anticoagulation may enter study successful conversion low molecular weight heparin No concurrent medication know adverse interaction treatment use trial ( e.g. , CYP3A4 inhibitors inducer phase I trial ) No prior concurrent live vaccine ( e.g. , measles , mumps , rubella , oral polio , Bacille CalmetteGuérin [ BCG ] , yellow fever , varicella , TY21a typhoid vaccine ) No concurrent grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>stage IV urethral cancer</keyword>
</DOC>